Dental Service Organizations: How DSO Structures Work and What They Mean for Taxes

The dental service organization, or DSO, is one of the most consequential structural shifts in the dental industry. It’s also one of the most misunderstood from a tax perspective. A DSO doesn’t own the dental practice in most states. What it owns is the management company that provides business services to the clinical entity, and the management fee paid between those two entities is where the tax structure lives. Whether you’re evaluating a DSO acquisition offer, considering setting up your own management company for a multi-location practice, or simply trying to understand what your colleagues are doing when they say they “sold to a DSO,” you need to understand how the money moves, how each entity is taxed, and where the IRS draws the line between a legitimate arrangement and one that doesn’t hold up.

What is a dental service organization, and why does the model exist?

A DSO is a management company that provides non-clinical business services to one or more dental practices. The model exists because of a legal doctrine called corporate practice of dentistry (CPD), which in most states prohibits non-dentists from owning or controlling a dental practice.

The CPD doctrine creates a problem for anyone who wants to invest in the economics of dental practices without being a licensed dentist. Private equity firms, corporate investors, and non-dentist entrepreneurs cannot simply buy a dental practice and hire dentists as employees the way they could buy a restaurant and hire cooks. The dentist must own the clinical entity. So the DSO model works around this restriction by separating the business into two pieces.

The first piece is the clinical entity, which is almost always a professional corporation (PC), professional limited liability company (PLLC), or similar professional entity required by state law. The clinical entity is owned by a licensed dentist or group of dentists. It employs (or contracts with) the dentists who treat patients. It holds the dental licenses, bears the professional liability, maintains patient relationships, and makes all clinical decisions. In the eyes of the state dental board, the clinical entity is the dental practice.

The second piece is the management entity, the DSO itself. This entity provides everything that isn’t clinical care: human resources, accounting, billing and revenue cycle management, marketing, IT infrastructure, equipment procurement, facilities management, insurance credentialing, compliance support, and strategic planning. The management entity signs a management services agreement (MSA) with the clinical entity, spelling out what services the DSO will provide and what the clinical entity will pay for them. The management entity can be owned by anyone, dentist or not, which is what allows private equity capital and non-dentist investors into the dental space.

The CPD doctrine varies by state. Texas has relatively permissive rules that allow DSO structures to operate with broad management authority. California enforces the doctrine more strictly and has pursued enforcement actions against arrangements that, in the state’s view, gave non-dentists de facto clinical control. New York, Florida, and most other states fall somewhere in between. The specific terms of the MSA, and whether it passes muster under a given state’s CPD rules, should be reviewed by a health care attorney before the arrangement goes into effect. But the fundamental concept is the same everywhere: the clinical entity provides patient care, the management entity provides business services, and a fee flows from one to the other.

How does the management fee work, and what keeps it at arm’s length?

The management fee is the single most important tax number in any DSO arrangement. It’s the revenue of the management entity and a deductible expense for the clinical entity under IRC 162 (ordinary and necessary business expenses). The fee must be at arm’s length, meaning it must reflect what an unrelated party would pay for the same services under comparable circumstances.

Most MSAs structure the management fee as a percentage of the clinical entity’s collections (net revenue actually received, not gross production billed). The typical range is 15% to 30%, though the exact percentage varies based on the scope of services the DSO provides, the size and profitability of the practice, the geographic market, and the leverage of the parties in the negotiation.

Three common fee structures appear in practice. The first is a flat percentage of collections, where the clinical entity pays the DSO a fixed percentage (say 20%) of everything it collects. This is simple and easy to administer, but it can overcompensate the DSO in high-collection months and undercompensate it in slow ones, since the DSO’s costs don’t necessarily scale linearly with the clinical entity’s revenue.

The second is a cost-plus model, where the DSO charges its actual costs of providing services plus a markup (often 10% to 15% above cost). This approach ties the fee more closely to the DSO’s actual expenses, which makes the arm’s-length argument easier to support, but it requires detailed cost tracking and a defensible markup percentage.

The third is a tiered or declining-percentage structure, where the management fee percentage decreases as collections rise. For example, 25% on the first $800,000 of collections, 20% on the next $400,000, and 15% on everything above $1.2 million. This structure reflects the reality that many DSO costs are relatively fixed (a single HR coordinator, one accounting system, one marketing platform), so the marginal cost of managing each additional dollar of revenue declines as the practice grows.

Regardless of which structure the MSA uses, IRC 482 gives the IRS the authority to reallocate income between related entities if the management fee doesn’t reflect an arm’s-length price. The IRS can increase or decrease the fee for tax purposes if it determines that the stated fee is above or below what unrelated parties would agree to. The regulations under IRC 482 specify several methods for establishing an arm’s-length price, including the comparable uncontrolled transaction (CUT) method, which compares the fee to what similar DSOs charge similar practices. A transfer pricing study, prepared by a qualified professional, documents the arm’s-length analysis and provides a defense if the IRS questions the fee.

Setting the fee too high is the more common risk in practice. If the management entity captures too large a share of the clinical entity’s revenue, the clinical entity’s profits look artificially low, and the dentist-owner’s compensation through the clinical entity may not reflect the economic reality of the practice. The IRS has incentive to challenge these arrangements because a fee that’s too high can shift income from a higher-tax entity to a lower-tax one, or from an entity in a high-tax state to one in a low-tax state.

Setting the fee too low is a business problem more than a tax problem. A management fee that doesn’t cover the DSO’s costs renders the DSO unsustainable. But if related parties are involved (for example, a dentist who owns both the clinical entity and the management entity), a below-market fee could still attract IRS scrutiny because it might indicate that the two entities aren’t genuinely separate.

How is each entity taxed in a DSO arrangement?

The clinical entity and the management entity are separate taxpayers, and each files its own return. The tax treatment depends on the entity type each one chooses, and those choices can vary independently.

The clinical entity is typically a PC, PLLC, or similar professional entity. It may elect S-corp treatment by filing Form 2553, which is common for single-dentist clinical entities because it splits income into W-2 salary (subject to FICA under IRC 3111 and 3101) and distributions (not subject to FICA). Multi-dentist clinical entities may operate as partnerships (LLC taxed as a partnership under the default rules) or elect S-corp treatment depending on their compensation model.

The clinical entity reports all of the practice’s patient revenue on its tax return. It then deducts the management fee paid to the DSO, along with all clinical operating costs: dentist compensation, clinical staff wages, dental supplies, lab fees, malpractice insurance, and any other expenses the clinical entity retains responsibility for under the MSA. The remainder passes through to the dentist-owner(s) as either W-2 salary plus S-corp distributions or as partnership income on Schedule K-1.

The management entity can be structured as an LLC (taxed as a disregarded entity, partnership, or S-corp), a C-corp, or an S-corp. The choice depends on who owns it.

When the same dentist owns both the clinical entity and the management entity (common in micro-DSO structures), the management entity is often a single-member LLC or an S-corp. The management fee flows through to the dentist’s individual return, and the main purpose of the separation is operational efficiency and, potentially, estate planning (more on this below).

When a private equity firm or outside investors own the DSO, the management entity is frequently a C-corp or a multi-member LLC. C-corp treatment is common for PE-backed DSOs because PE fund structures and their institutional investors are not eligible S-corp shareholders under IRC 1361(b)(1). The C-corp pays corporate income tax on its net income (the management fee minus operating costs), and any distribution to shareholders is taxed again at the dividend rate, producing the familiar double-tax structure. PE-backed DSOs often retain earnings for reinvestment rather than distributing dividends, deferring the second layer of tax until a future exit event.

The management entity’s deductible expenses include staff salaries (administrative, marketing, HR, IT), technology and software, marketing costs, facilities costs (if the DSO holds the leases), insurance, and amortization of any acquired intangibles. If the DSO acquired the management rights through a purchase (as in a PE roll-up), the acquired goodwill and intangibles are amortizable over 15 years under IRC 197.

An important nuance: because the clinical entity’s revenue includes the management fee before it’s paid, the management fee functions as a reallocation of gross revenue from the clinical entity to the management entity. The total taxable income across both entities (before considering entity-type differences) is the same as if the practice operated as a single entity. The tax savings, when they exist, come from the entity-type differences (pass-through vs. C-corp treatment), the ability to deduct different expenses in different entities, or the allocation of income among owners in different tax brackets.

What happens when a dentist sells to a private equity-backed DSO?

The PE-backed DSO acquisition is the transaction most dentists are thinking about when they hear the word “DSO.” The structure is more complex than a traditional practice-to-practice sale, and the tax treatment is substantially different.

In a PE-backed DSO acquisition, the private equity firm doesn’t buy the dental practice itself (it can’t, because of the CPD doctrine). Instead, the transaction is structured in several layers. The PE firm acquires (or creates) a management entity and enters into a long-term MSA with the clinical entity. The selling dentist transfers the non-clinical assets of the practice (equipment, leases, administrative staff, the management infrastructure) to the management entity in exchange for a purchase price. The selling dentist retains ownership of the clinical entity and typically enters into a professional services or employment arrangement to continue providing clinical care.

The purchase price in a PE-backed DSO acquisition is typically expressed as a multiple of the practice’s EBITDA (earnings before interest, taxes, depreciation, and amortization). Platform acquisitions, where the PE firm is building a new DSO around the selling dentist’s practice, commonly trade at 5x to 10x EBITDA. Add-on acquisitions, where the PE firm is bolting the practice onto an existing DSO platform, trade at lower multiples, often 4x to 7x EBITDA. By comparison, traditional practice-to-practice sales typically price at 65% to 85% of annual collections, or 1.5x to 3.5x SDE (seller’s discretionary earnings). The difference between a $400,000 purchase price for a traditional sale and a $2.8 million purchase price for a PE roll-up of the same practice is what makes these offers so compelling to selling dentists.

The purchase price allocation follows IRC 1060. The total price is allocated across seven classes of assets, from cash (Class I) through goodwill and going-concern value (Class VII). Equipment is allocated to Class V and triggers depreciation recapture under IRC 1245 (ordinary income). Covenants not to compete are Class VI, also ordinary income to the seller and a 15-year Section 197 intangible for the buyer. Goodwill absorbs the residual, and for most dental practice sales, goodwill is 60% to 80% of the total price.

Earnout provisions are extremely common in DSO acquisitions. The PE firm rarely pays the full purchase price at closing. A typical structure might be 60% to 70% of the price at closing, with the remaining 30% to 40% contingent on the selling dentist meeting production or EBITDA targets over a 3-to-5 year earnout period. The tax treatment of contingent consideration depends on whether the installment method under IRC 453 applies. If the earnout has a stated maximum, installment treatment is generally available, and the seller recognizes gain as payments arrive. If the maximum is not determinable, the rules in Treas. Reg. 15A.453-1(c) may require a different reporting approach.

The selling dentist’s post-sale compensation also matters. After the sale, the dentist typically receives compensation through two channels: a salary or professional service fee from the clinical entity (for clinical work) and, in some structures, an ongoing interest in the management entity (equity rollover). The equity rollover is common in PE deals: the selling dentist reinvests a portion of the sale proceeds (often 10% to 30%) back into the DSO platform, becoming a minority shareholder in the management entity alongside the PE firm. The rollover itself may qualify for tax-deferred treatment under IRC 351 if structured properly, but the terms vary by deal.

What are the IRS and state-level risks in a DSO arrangement?

The IRS examines DSO arrangements through several lenses, and a practice that trips one of these triggers can face recharacterization, income reallocation, or penalties.

The most common federal risk is an above-market management fee. Under IRC 482, the IRS can reallocate income between the clinical entity and the management entity if the fee doesn’t reflect what unrelated parties would agree to. The consequence is a two-sided adjustment: the clinical entity’s deduction for the fee is reduced, increasing its taxable income, and the management entity’s revenue is correspondingly reduced. If the reallocated amounts are large enough, penalties under IRC 6662(e) (substantial and gross valuation misstatements for transfer pricing) can apply, and those penalties are 20% or 40% of the tax underpayment, depending on the degree of the misstatement. A contemporaneous transfer pricing study, prepared before the return is filed, is the primary defense and can eliminate or reduce penalties.

The second federal risk is recharacterization of the arrangement. If the IRS determines that the DSO exercises effective control over the clinical entity, the two entities may not be treated as separate for tax purposes. In the extreme case, the IRS could treat the management fee as a meaningless payment between divisions of a single taxpayer. This risk is highest when the DSO dictates clinical staffing, sets treatment protocols, controls patient scheduling to the point of dictating clinical workflow, or has the unilateral right to replace the dentist-owner. The more the MSA reads like an employment agreement with a clinical label, the greater the recharacterization risk.

A related risk is the disguised sale theory. If the structure of the DSO arrangement, combined with the management fee terms, effectively transfers the economic benefit of the practice to the management entity’s owners without a purchase price being paid, the IRS could treat the arrangement as a sale in substance, with the management fee serving as installment payments. This theory has been applied in other industries (physician practice management companies in the 1990s saw several of these challenges), and the IRS has the analytical framework to apply it to dental DSOs.

State-level risks are at least as significant as the federal ones. The CPD doctrine, while primarily a professional regulation matter rather than a tax matter, can have tax consequences if violated. If a state dental board or attorney general determines that the DSO arrangement violates the state’s CPD rules, the MSA can be voided, and the management fees paid under it may lose their deductibility (payments under a void contract are generally not deductible as ordinary and necessary business expenses). California, New York, and Illinois have all pursued enforcement actions against DSO arrangements they viewed as giving non-dentists clinical control.

Fee-splitting prohibitions add another layer. Some states prohibit dentists from sharing professional fees with non-dentists. The management fee in a DSO arrangement is technically a payment for management services, not a fee split, but the distinction can be thin. If the management fee is calculated as a straight percentage of collections and the DSO provides no identifiable services beyond profit-sharing, a state regulator may characterize it as fee-splitting.

Documentation is the thread that connects all of these risks. A defensible DSO arrangement requires a written MSA with clearly defined services, a management fee supported by a transfer pricing analysis, documented separation between clinical and management functions, separate books and records for each entity, separate bank accounts, separate governance (board minutes, resolutions, operating agreements that reflect genuine independence), and evidence that clinical decisions are made by the clinical entity. When the documentation is weak, every other risk is amplified.

Should a multi-location dentist set up their own DSO?

A dentist who owns two or more practices, or who is planning to acquire additional locations, may benefit from creating a management entity to centralize the business functions. This is sometimes called a “friendly DSO” or “micro-DSO,” and the structure mirrors the PE-backed model but with the same dentist (or the dentist’s family) controlling both sides.

The basic structure works as follows. The dentist forms a management LLC (or S-corp). Each clinical practice operates through its own professional entity (PC or PLLC) in whatever state it’s located, because professional entity requirements and dental licenses are state-specific. The management LLC signs an MSA with each clinical entity, providing centralized services: a shared administrative team, one accounting function, a single marketing program, centralized purchasing (which produces volume discounts on supplies and equipment), one IT platform, and standardized systems across locations. Each clinical entity pays the management LLC a fee for these services.

The benefits are operational and, potentially, related to estate planning. On the operational side, a centralized management entity eliminates duplicated effort. Instead of each practice having its own bookkeeper, office manager, and marketing vendor, the management LLC employs a single team that serves all locations. Purchasing leverage matters: a management entity buying supplies for five locations can negotiate better pricing than any one practice can on its own. And standardized systems (the same practice management software, the same recall protocols, the same billing workflow) make it easier to manage and grow.

The estate planning angle is more nuanced. The management entity’s value, which represents the earnings power of the management function, can be separated from the clinical entities’ value. The dentist might transfer ownership of the management LLC (in whole or in part) to a family trust, a spouse, or children who are not dentists. Because the management entity is not a professional entity, it’s not subject to the ownership restrictions that apply to the clinical entities. Over time, as the management entity earns fees and grows in value, that value accrues to the transferees rather than to the dentist’s estate. This is conceptually similar to an estate freeze, and it can be effective, but it must be structured carefully. The IRS will scrutinize the valuation of the management entity at the time of transfer, and the management fee must be genuinely arm’s length (not inflated to shift income to the family-owned entity). Gift and estate tax implications also apply, and the transfer should be reviewed under IRC 2036 (retained interests) and IRC 2701 (special valuation rules for transfers to family members).

The risks for a self-built DSO are the same as for a PE-backed one, with an added wrinkle: when the same person or family controls both entities, the IRS has an easier time arguing that the separation is artificial. The management fee becomes a mechanism for moving money between pockets rather than compensating an independent service provider. To withstand scrutiny, the management entity must provide real services, charge a fee that an independent practice would pay for those services, maintain separate records and bank accounts, and operate with genuine organizational independence from the clinical entities.

The break-even point for a self-built management entity depends on the number of locations and the volume of centralized services. A dentist with two locations in the same city may not generate enough management expense to justify the cost of maintaining a separate entity (legal fees, separate return preparation, transfer pricing documentation). A dentist with four or more locations across multiple states has a stronger case, because the management overhead is substantial enough to be genuinely centralizable, and the multi-state footprint adds administrative complexity that a single management entity can absorb.

What should I do next?

Whether you’re evaluating a DSO offer, planning a multi-practice expansion, or just trying to understand how the model works before making a decision, the structure of the arrangement and the management fee are the two issues that determine the tax outcome.

If you’ve received an offer from a PE-backed DSO, the purchase price multiple is only the starting point. The IRC 1060 allocation, the earnout terms, the non-compete scope, the post-sale compensation structure, and the equity rollover all affect the after-tax proceeds. A tax advisor should model the full transaction before you sign a letter of intent.

If you’re considering building your own management entity for a multi-location practice, the arm’s-length fee and the documentation of genuine separation between the clinical and management functions are the issues that will determine whether the arrangement survives IRS and state-level scrutiny.

Related guides for the topics that intersect with DSO structures:

• Dental practice entity structure: LLC, S-corp, and partnership, covering the entity-type election for the clinical entity that sits inside a DSO arrangement
• Dental practice valuation and sale, covering the IRC 1060 allocation and the personal vs. enterprise goodwill distinction that applies when selling to a DSO
• Dental practice bookkeeping and overhead benchmarks, covering the financials that feed the management fee calculation and the EBITDA figure that drives the purchase price multiple
• Franchise and multi-unit tax planning, the parallel multi-entity holding company structure for franchise businesses, with comparable management-fee and transfer-pricing considerations

This guide is general information, not tax advice for your specific situation. Which points apply, and how, depends on your facts.